Takeda secured Indonesia’s plasma fractionation license and will invest up to $30 million to establish a plasma donation network and advance PDMP manufacturing.
Written By: Samiksha Jadhav, BPharm
Reviewed By: Pharmacally Editorial Team
Indonesia has granted Takeda a plasma fractionation license, marking a major step in the country’s plan to strengthen domestic production of plasma-derived medicinal products (PDMPs) and improve long-term access to these essential therapies. The collaboration between Takeda and the Indonesian Government includes an initial investment of up to US$30 million to establish a pilot plasma donation network and assess the feasibility of local PDMP manufacturing.
The license, issued by Indonesia’s Ministry of Health, enables Takeda to collect and fractionate plasma as part of a multi-phase initiative involving the Ministry of Health, the Ministry of Investment and Downstream Industry/BKPM, and the Coordinating Ministry for Economic Affairs. The program also supports Indonesia’s broader strategy to expand biopharmaceutical manufacturing capacity and strengthen healthcare resilience.
Why Plasma-Derived Medicinal Products Matter
Plasma-derived medicinal products are biologic medicines produced from human plasma and are used to treat a range of rare, chronic, and life-threatening conditions, including primary immunodeficiency disorders, bleeding disorders such as hemophilia, neurological diseases, and other serious immune-mediated conditions. Global demand for these therapies continues to increase, while many countries across Southeast Asia face limited plasma collection capacity and inconsistent access to treatment.
Takeda to Launch Plasma Donation Network
As part of the first phase, Takeda will establish plasma donation centers over the next two years using the company’s BioLife plasma center model. The pilot will evaluate operational feasibility before potential expansion into a nationwide plasma donation network. The first plasma donation center is expected to begin operations in 2027.
During the pilot phase, plasma collected in Indonesia will be processed through Takeda’s existing global fractionation network while the company evaluates technical, regulatory, and commercial requirements for constructing a plasma-derived therapy manufacturing facility within Indonesia. If developed, the facility could supply both domestic demand and international markets while strengthening the global PDMP supply chain.
Investment Supports Workforce and Manufacturing Capacity
The plasma donation centers will operate under international quality and regulatory standards and will support workforce development through specialized training for healthcare professionals, laboratory personnel, and technical staff. The investment is also expected to create skilled employment opportunities and facilitate technology transfer in advanced plasma collection and biopharmaceutical manufacturing.
Leaders Highlight Strategic Healthcare Partnership
Indonesia’s Minister of Health, Budi Gunadi Sadikin, said the initiative supports the country’s strategy to build sustainable healthcare capabilities and improve access to essential and innovative therapies.
Takeda’s President of Plasma-Derived Therapies, Ramy Riad, said the collaboration extends the company’s long-standing presence in Indonesia and reflects its commitment to expanding global access to plasma-derived medicinal products while strengthening local healthcare infrastructure and manufacturing expertise.
Indonesia’s Minister of Investment and Downstream Industry and Chairman of BKPM, Rosan P. Roeslani, said the project combines strategic investment with technology transfer, workforce development, and industrial growth, supporting the country’s ambition to become a regional center for advanced life sciences and biopharmaceutical manufacturing.
Global Regulatory Context
Indonesia’s initiative aligns with a broader global effort to strengthen domestic plasma supplies. Earlier this month, the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) permitted UK donor plasma to be used for manufacturing five additional plasma-derived medicinal products, removing another restriction introduced in 1999 over variant Creutzfeldt-Jakob disease (vCJD). The decision reflects growing regulatory confidence in modern plasma safety measures and efforts to improve long-term supply resilience.
Path Forward
The collaboration represents the first initiative of its kind in the Association of Southeast Asian Nations (ASEAN) to establish an integrated plasma ecosystem. The first plasma donation center is expected to open in 2027, while feasibility studies for a local manufacturing facility continue. Beyond improving Indonesia’s domestic supply of plasma-derived medicinal products, the initiative could strengthen regional plasma collection capacity and enhance the long-term availability of lifesaving therapies across Southeast Asia and the global market.
Reference
Takeda and Indonesian Government Announce Plasma-Derived Therapies Collaboration
About the Writer
Samiksha Vikram Jadhav (LinkedIn) is a B. Pharm graduate with a strong academic foundation in pharmaceutical sciences, pharmacology, and drug development. She specializes in pharma market research, with a focused interest in mergers and acquisitions, strategic partnerships, and global pharma and biotech deals. Her work centers on analyzing industry transactions, market positioning, and business strategies, translating complex developments into clear, accurate, and insightful scientific and commercial reporting.